Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea Capsules Compared to Placebo After an Initial 12 Week Treatment Regimen With Oracea and MetroGel 1% in Adults With Rosacea

Trial Profile

Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea Capsules Compared to Placebo After an Initial 12 Week Treatment Regimen With Oracea and MetroGel 1% in Adults With Rosacea

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxycycline hyclate (Primary) ; Metronidazole
  • Indications Bacterial infections; Rosacea
  • Focus Therapeutic Use
  • Sponsors Galderma Research & Development
  • Most Recent Events

    • 08 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 19 Jun 2013 Planned End Date changed from 1 Jan 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 25 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top